Formulation Development
RS BioTherapeutics Announces Research Collaboration With University of Colorado School of Medicine
RS BioTherapeutics recently announced a collaboration agreement with the University of Colorado School of Medicine to evaluate use of its first-in-class, steroid-free therapeutic platform in…
Iktos Acquires Synsight, a Company Specializing in Protein-Protein & RNA-Protein Interactions-Targeted Drug Discovery
Iktos recently announced the acquisition of Synsight, a French biotech company applying AI and high-content cell imaging to the discovery of novel drug candidates. The…
CellProthera & BioCardia Collaborate on Successful Phase 2 Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction
CellProthera and BioCardia Inc. recently announced success from a collaborative Phase 2 trial of ProtheraCytes for the treatment of acute myocardial infarction (AMI) led by…
HilleVax Reports Topline Data From NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
HilleVax, Inc. recently announced topline data results from NEST-IN1. NEST-IN1 is a Phase 2b, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy, safety, and…
CERo Therapeutics Presents CER-1236 Data Supporting Use in AML
CERo Therapeutics Holdings, Inc. recently announced the presentation of a poster on its lead compound CER-1236 at the Global Cell & Gene Therapy Summit 2024.…
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical-Stage Pharmaceutical Portfolio to Publicly Traded Company
SciSparc Ltd. recently announced it signed a non-binding letter of intent (LOI) to spin off its advanced clinical-stage pharmaceutical portfolio and its equity stake in…
Silo Pharma Announces Exclusive Global License for Lead Candidate
Silo Pharma, Inc. recently announced it has entered into an exclusive, global license agreement with Columbia University to further develop, manufacture, and commercialize its lead…
CureVac Initiates Strategic Restructuring to Align Resources With Focus on High-Value mRNA Pipeline Opportunities
CureVac N.V. recently announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet…
Medigene AG Expands Patent Portfolio With the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor
Medigene AG recently announced it has been issued a patent by the Chinese Patent Office protecting its T cell receptor (TCR) targeting NY-ESO-1 (New York…
IntelGenx Obtains Preliminary Efficacy Results for the BUENA Montelukast VersaFilm Phase 2a Clinical Trial in Patients With Mild to Moderate Alzheimer’s Disease
IntelGenx Corp. has successfully completed the BUENA Alzheimer’s disease (AD) study. The BUENA study was designed as a Phase 2a proof of concept study to…
Apollomics Announces Updated Strategic Focus & Leadership Team Changes
Apollomics Inc. recently announced an updated strategic focus for the clinical development of vebreltinib by focusing on NSCLC patients with Met Amplification, as well as…
Sobi Initiates Rolling BLA to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout
Sobi recently announced the initiation of a rolling Biologics License Application (BLA) to the USA FDA for SEL-212. The submission is based on the results…
Cellular Origins Acquires ACTIA Platform IP to Enhance Automated Cell Therapy Manufacturing
Cellular Origins recently announced the acquisition of the ACTIA (Autologous Cell Therapy Industrial Automation) Platform IP, developed by Geoff Hodge whilst CEO of SOTIO Biotech…
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. recently announced positive topline results from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG). Descartes-08, Cartesian’s lead…
Annovis Bio Announces New Data From Phase 3 Parkinson’s Study
Annovis Bio Inc. recently announced new data from its Phase 3 PD study demonstrating that buntanetap is safe and effective in improving motor and non-motor…
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
Inozyme Pharma, Inc. recently announced the US FDA has granted Fast Track designation to INZ-701 for the treatment of ABCC6 Deficiency. “Through Fast Track designation,…
Alvotech Announces Positive Topline Results for a Proposed Biosimilar for Prolia & Xgeva
Alvotech recently announced positive topline results from a confirmatory patient study for AVT03, a proposed biosimilar to Prolia (denosumab) and Xgeva (denosumab). The study met…
Touchlight & LenioBio Collaborate to Accelerate Development of Protein Therapeutics for Pandemic Response
LenioBio and Touchlight recently announced a supply agreement aimed at leveraging the revolutionary capabilities of Touchlight’s rapid enzymatic doggybone DNA (dbDNA) to achieve unprecedented speed…
Navin Molecular to Invest Up to $35 Million to Expand GMP Manufacturing Capabilities
Navin Molecular recently announced a $35-million investment to construct a 9,000-square-meter GMP manufacturing plant in Dewas, India. The new facility will nearly double overall capacity…
Ovid Therapeutics & Graviton Bioscience Announce Topline Data From Phase 1 Clinical Trial Studying a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
Ovid Therapeutics Inc. and Graviton Bioscience Corporation recently announced the results from their Phase 1 healthy volunteer study evaluating the safety, tolerability, and pharmacokinetic (PK)…
